Phuturdex › Diseases › Urologic Neoplasms
Drugs in development · updated 30 October 2026
Urologic Neoplasms: drugs in development
As of 30 October 2026 there are 21 active clinical trials (recruiting or ongoing, phases I–III) on 35 drugs for urologic Neoplasms. 12 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| NDV01 | III | 1 | NCT07464145 |
| SavolitinibAZD6094 | III | 1 | NCT03091192 |
| Vepugratinib | II | 2 | NCT07827612 |
| CadonilimabAK104, Candonilimab | II | 1 | NCT06427057 |
| Iparomlimabiparomilimab | II | 1 | NCT07741617 |
| Izalontamab brengitecanBL-B01D1, BMS-986507 | II | 1 | NCT05785039 |
| SasanlimabZumrad® | II | 1 | NCT05241340 |
| Tuvonralimab | II | 1 | NCT07741617 |
| TYRA-300 | I–II | 1 | NCT05544552 |
| LY4052031 | I | 1 | NCT06465069 |
| LY4101174 | I | 1 | NCT06238479 |
| SI-B036 | I | 1 | NCT07744243 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PembrolizumabKEYTRUDA, MK-3475 | III | 5 | NCT07566156 |
| Enfortumab VedotinPadcev® | III | 2 | NCT07566156 |
| GemcitabineGemcitabin, Gemzar | III | 2 | NCT07566156 |
| SunitinibSutent®, Sunitinib Accord® | III | 2 | NCT03091192 |
| CisplatinCis Platinum, Cisplatine | III | 1 | NCT07566156 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 1 | NCT07566156 |
| Mitomycin CMitomycin, Jelmyto | III | 1 | NCT07566156 |
| RivaroxabanRivoroxaban, Yulzety® | II–III | 1 | NCT05920343 |
| CabozantinibResniben®, Cabometyx® | II | 1 | NCT03541902 |
| CarboplatinCarboplatine, Paraplatin | II | 1 | NCT06353906 |
| FulvestrantCligavyx®, Faslodex® | II | 1 | NCT04579380 |
| LenvatinibLenvatinib Mesilate Capsules, Levatinib | II | 1 | NCT07741617 |
| NivolumabOpdivo, ONO-4538 | II | 1 | NCT06237920 |
| PaclitaxelTaxol, Paxlitaxel | II | 1 | NCT06353906 |
| Relatlimab | II | 1 | NCT06237920 |
Sorted by most advanced phase and number of active trials. Showing 15 of 23 drugs.
All 35 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Renal cell carcinoma 228 drugs
- Bladder neoplasm 185 drugs
- Non-small-cell lung carcinoma 726 drugs
- Kidney neoplasm 92 drugs
- Transitional cell carcinoma 146 drugs
- Melanoma 352 drugs
- Non-muscle invasive bladder neoplasm 50 drugs
- Colorectal neoplasm 534 drugs
- Ovarian neoplasm 411 drugs
- Metastasis 493 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Stomach neoplasm 340 drugs
Broader categories
- Female urogenital diseases and pregnancy complications 3 drugs
- Female urogenital disease 11 drugs
- Urogenital Diseases 16 drugs
- Urologic Diseases 16 drugs
- Male urogenital disease 19 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D014571 “Urologic Neoplasms”.